These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16873827)

  • 1. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Bowker et Al.
    Farooki A; Schneider SH
    Diabetes Care; 2006 Aug; 29(8):1989-90. PubMed ID: 16873827
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Aug; 29(8):1990-1. PubMed ID: 16873829
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diabetes in the elderly. Reflections by a practitioner in diabetology].
    Curchod B
    Schweiz Rundsch Med Prax; 1990 Aug; 79(35):1005-7. PubMed ID: 2218218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Mühlhauser I; Sawicki PT; Berger M
    Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypoglycemic drugs.
    White JR; Campbell RK
    Clin Podiatr Med Surg; 1992 Apr; 9(2):239-55. PubMed ID: 1586902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination therapy with insulin and sulfonylurea].
    Bachmann W
    Dtsch Med Wochenschr; 1988 Apr; 113(16):652-4. PubMed ID: 3282863
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary failure to sulfonylureas in NIDDM. Are sulfonylureas still useful?
    Menon KN; Seshadri MS
    J Assoc Physicians India; 1990 Aug; 38(8):533-4. PubMed ID: 2123182
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased cancer mortality in type 2 diabetes (ZODIAC-3).
    Landman GW; Ubink-Veltmaat LJ; Kleefstra N; Kollen BJ; Bilo HJ
    Anticancer Res; 2008; 28(2B):1373-5. PubMed ID: 18505082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case from practice (158). Type I diabetes in remission. Type II diabetes].
    Skoda C; Spinas GA
    Schweiz Rundsch Med Prax; 1990 Jan; 79(1-2):25-6. PubMed ID: 2404332
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
    Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy for type 2 diabetes.
    Bell DS
    Am Fam Physician; 2001 Dec; 64(11):1812, 1814. PubMed ID: 11764861
    [No Abstract]   [Full Text] [Related]  

  • 13. QT-interval dispersion in type 2 diabetic and non-diabetic patients with post-myocardial infarction.
    Sakabe K; Fukuda N; Fukuda Y; Wakayama K; Nada T; Morishita S; Shinohara H; Tamura Y
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):121-6. PubMed ID: 17346952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic effect of augmentation strategies in patients with type 2 diabetes initiated on sulfonylureas.
    Kalsekar I; Latran M
    Manag Care Interface; 2007 Sep; 20(9):39-46. PubMed ID: 18161391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.
    Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
    Charbonnel B
    Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
    Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
    Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoplasmic reticulum stress in beta cells: latent mechanism of secondary sulfonylurea failure in type 2 diabetes?
    Qian L; Zhang S; Xu L; Peng Y
    Med Hypotheses; 2008 Dec; 71(6):889-91. PubMed ID: 18786775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.